Biogen Idec Incorporated

DUBLIN/NEW YORK (Reuters) - Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm. Royalty Pharma, which buys...

NEW YORK (Reuters) - U.S. stocks ended little changed on Monday with indexes hovering near record levels as concerns about a correction cut earlier gains that were boosted by acquisition activities. Based on the latest available data, the Dow Jones...

LONDON, May 20 (Reuters) - U.S. investor Royalty Pharma raised its offer to $12.50 per share for Irish drugmaker Elan on Monday, representing a premium of 45 percent to Elan's enterprise value, it said. The company said it was offering $4.6 billion for...

(Reuters) - XenoPort Inc said it would stop development of an experimental multiple sclerosis treatment it planned to launch in 2015 after a late-stage trial failed to show significant improvement over a placebo. Shares of the company fell 26 percent...

May 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S. companies, including Macy's and Biogen Idec on Friday. HIGHLIGHTS * Aruba Networks : FBN, JP Morgan, Needham, Wedbush, Wells Fargo cut rating *...

(Corrects paragraph 12 to show Biogen has stake in new drug) By Bill Berkrot May 15 (Reuters) - An experimental leukemia treatment that Roche Holding AG hopes will improve upon its best-selling cancer drug Rituxan delayed disease progression twice as...

DUBLIN, May 15 (Reuters) - Royalty Pharma last year urged Elan to hold off on a multi-billion dollar drug deal until it had taken the Irish drugmaker private to boost the compensation the firms' executives would receive, Elan said on Wednesday. Royalty...

Por Padraic Halpin DUBLIN (Reuters) - Elan intensificó el lunes su intento por mantener su independencia al alcanzar un acuerdo de 1.000 millones de dólares para comprar el 21 por ciento de las regalías que la firma estadounidense Theravance recibe de...

DUBLIN (Reuters) - Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma. Elan, battling to keep its...

* Elan to acquire newly approved Breo as part of $1 bln deal * Irish drugmaker to announce further deals in due course * Looks to outmanoeuvre Royalty with second shareholder dividend By Padraic Halpin DUBLIN, May 13 (Reuters) - Elan stepped up its...

May 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S. companies, including Yahoo and News Corp, on Thursday. HIGHLIGHTS * Yahoo : Raymond James raises price target to $30 from $27; rating outperform...

(For other news from Reuters Health Summit, click on http://www.reuters.com/summit/Health13) By Ben Hirschler NEW YORK, May 8 (Reuters) - A pickup in new drug approvals, the promise of faster regulatory decisions and more targeted medicines have...